Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
CYC-116
Cat. No.:
0225LY-0658
Appearance:
Solid
Purity:
≥97%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
CYC116 is a potent Aurora A and B inhibitor (Ki: 8.0/9.2 nM) in Phase 1 trials that also targets VEGFR2 (Ki: 44 nM), while showing no activity against PKA, Akt, PKC, or Plk1 and demonstrating 50-fold higher potency over CDKs.
Synonym:
693228-63-6; 4-methyl-5-(2-(4-morpholinophenylamino)pyrimidin-4-yl)thiazol-2-amine; 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine; 4-methyl-5-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)thiazol-2-amine; 2-Pyrimidinamine,4-(2-amino-4-methyl-5-thiazolyl)-N-[4-(4-morpholinyl)phenyl]-; 4-(2-amino-4-methyl-1,3-thiazol-5-yl)-N-[4-(morpholin-4-yl)phenyl]pyrimidin-2-amine
CAS No.:
693228-63-6
Compound CID:
6420138
Formula:
C18H20N6OS
Formula Weight:
368.46
Specification
Targets&IC50:
Aurora A: 8 nM(Ki); Aurora B: 9.2 nM(Ki)
Relative Density:
1.355 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
CYC-116 can be used in kinase research to evaluate the dual inhibition of Aurora kinases and VEGFR.
Library Information
Target:
FLT; VEGFR; Aurora kinase; CDK; S6 Kinase
Receptor:
Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2
Pathways:
Chromatin/Epigenetic; Cell cycle/Checkpoint; PI3K/Akt/mTOR signaling; Angiogenesis; MAPK; Tyrosine kinase/adaptors
Plate Number:
AOCL-9
Plate Location:
e4
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
13.4 mg/mL; 36.37 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
ALogP:
2.743
HBA_Count:
4
HBD_Count:
2
Rotatable Bond:
4
